查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1576773

Gabapentin市場：依產品、給藥途徑、效力、應用、通路 - 2025-2030 年全球預測

Gabapentin Market by Product (Capsule, Tablet), Route of Administration (Oral, Parenteral), Medication, Application, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年Gabapentin市場價值為22.2億美元，預計2024年將達到23.2億美元，預計複合年成長率為4.38%，到2030年將達到30億美元。

Gabapentin是一種抗驚厥藥物，在醫藥市場上應用廣泛，主要用於治療神經病變疼痛和痙攣。這種需求源於其在神經相關疼痛管理方面的有效性，有助於改善慢性疼痛疾病和癲癇患者的生活品質。Gabapentin的應用超出了這些主要用途，還包括仿單標示外用途，例如治療焦慮症和不安腿症候群，從而擴大了最終用途的範圍。市場洞察表明，神經病變疼痛疾病盛行率的增加和老年人口的增加是關鍵的成長動力。此外，對非鴉片類疼痛管理解決方案不斷成長的需求進一步增加了Gabapentin在市場上的存在。越來越多的專注於擴大Gabapentin丁治療用途的研究正在為市場創造機會，使製藥公司能夠投資臨床試驗以探索更廣泛的用途。然而，市場面臨來自替代療法的競爭、潛在副作用、對仿單標示外使用的監管審查以及影響品牌產品的專利到期等挑戰。法規環境也是一個限制因素，因為如果非常規用途未經核准，市場擴張可能會受到阻礙。為了克服這些障礙，精準醫學和基因分析等創新研究可能會發現具有特定治療需求的新患者群體並推動有針對性的配方。緩釋性和新型聯合治療等遞送機制的進步也有可能提高患者的依從性和療效。此外，與醫療保健提供者夥伴關係以更好地了解患者需求並最佳化Gabapentin的使用可以進一步推動市場滲透。這就是為什麼了解疼痛管理、監管更新和競爭發展的持續發展非常重要。透過技術整合利用資料為公司提供了對患者偏好的洞察，並使行銷策略能夠提高Gabapentin的市場地位並確保永續成長。該市場的動態本質要求注重戰略敏捷性和研究主導的創新，以有效地利用新機會。

主要市場統計
基準年[2023] 22.2億美元
預測年份 [2024] 23.2億美元
預測年份 [2030] 30億美元
複合年成長率（%） 4.38%

市場動態：揭示快速發展的Gabapentin市場的關鍵市場洞察

Gabapentin市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 慢性疼痛和相關疾病的增加增加了對有效治療方案的需求
    • 將Gabapentin入多重藥物疼痛管理方案以加速臨床實務中的採用
    • 旨在改善基本藥物取得的政府措施和醫療保健政策
  • 市場限制因素
    • 來自替代療法、仿冒品和廉價藥品的競爭
  • 市場機會
    • 獸醫領域對Gabapentin用於寵物和牲畜疼痛管理的需求不斷成長
    • Gabapentin作為治療纖維肌痛和相關慢性疼痛綜合症的藥物的出現
    • 開發Gabapentin聯合治療提高神經系統疾病的治療效果
  • 市場挑戰
    • 人們越來越擔心潛在的副作用和濫用

波特五力：駕馭Gabapentin市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解Gabapentin市場的外部影響

外部宏觀環境因素在塑造Gabapentin市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解Gabapentin市場的競爭狀況

Gabapentin市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣Gabapentin市場供應商的績效評估

FPNV定位矩陣是評估Gabapentin市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製Gabapentin市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，Gabapentin市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性疼痛及相關疾病發生率的上升增加了對有效治療方法的需求
      • 將Gabapentin噴丁納入多模態疼痛管理方案並促進臨床實踐中的採用
      • 強調基本藥物的可得性和可負擔性的政府措施和醫療保健政策
    • 抑制因素
      • 來自替代療法、假藥和廉價藥物的競爭
    • 機會
      • 用於寵物和牲畜疼痛管理的獸藥對Gabapentin的需求不斷成長
      • Gabapentin作為治療纖維肌痛和相關慢性疼痛綜合症的重要藥物的出現
      • 開發Gabapentin噴丁聯合治療增強神經系統疾病的治療效果
    • 任務
      • 對潛在副作用和濫用的擔憂增加
  • 市場區隔分析
    • 劑型：膠囊是首選，因為選擇方便且容易
    • 用途：廣泛用作局部性癲癇發作的輔助性治療，以穩定神經活動並降低癲癇發作頻率。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章Gabapentin市場：依產品

  • 膠囊
  • 錠劑

第7章Gabapentin市場：依給藥途徑

  • 口服
  • 胃腸外的

第8章Gabapentin藥物市場

  • 品牌
  • 非專利的

第9章Gabapentin市場：依應用分類

  • 焦慮
  • 癲癇
  • 神經病變疼痛
  • 不寧腿

第10章Gabapentin市場：按分銷管道

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章 美洲Gabapentin市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章 亞太地區Gabapentin市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲Gabapentin市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Stride Pharma 獲得美國FDA核准用於神經科治療Gabapentin
    • Lotus 和 Adalbo 在韓國推出Gabapentin丁緩釋製劑
  • 戰略分析和建議
Product Code: MRR-3204321AF706

The Gabapentin Market was valued at USD 2.22 billion in 2023, expected to reach USD 2.32 billion in 2024, and is projected to grow at a CAGR of 4.38%, to USD 3.00 billion by 2030.

Gabapentin, an anticonvulsant medication, has a broad scope within the pharmaceutical market, predominantly used to treat neuropathic pain and seizures. Its necessity arises from its effectiveness in managing nerve-related pain conditions, contributing to quality of life improvements for individuals with chronic pain disorders and epilepsy. The application of gabapentin extends beyond these primary uses, also encompassing off-label uses such as managing anxiety disorders and restless leg syndrome, thus widening its end-use scope. Market insights reveal that the growing prevalence of neuropathic pain conditions and the increasing geriatric population are key growth drivers. Additionally, the rise in demand for non-opioid pain management solutions further propels gabapentin's market presence. Opportunities within the market are emerging from the increasing research focused on expanding gabapentin's therapeutic applications, allowing pharmaceutical companies to invest in clinical trials exploring broader uses. However, the market faces challenges, including competition from alternative therapies, potential side effects, regulatory scrutiny concerning off-label uses, and patent expirations impacting branded versions. Regulatory environments also pose limitations, as non-approval for non-traditional uses could stymie market expansion. To navigate these obstacles, innovative areas of research such as precision medicine and genetic profiling could uncover new patient segments with specific therapeutic needs, driving targeted gabapentin formulations. Advancing delivery mechanisms, such as sustained-release formats or novel combination therapies, could also enhance patient compliance and efficacy. Moreover, partnerships with healthcare providers to better understand patient needs and optimize gabapentin use can further market penetration. Therefore, staying attuned to continuous developments in pain management, regulatory updates, and competitive activities is crucial. Harnessing data through technology integration could offer businesses insights into patient preferences, enabling tailored marketing strategies that enhance gabapentin's market position while ensuring sustainable growth. This dynamic nature of the market necessitates strategic agility and a focus on research-driven innovation for leveraging emerging opportunities effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 2.22 billion
Estimated Year [2024] USD 2.32 billion
Forecast Year [2030] USD 3.00 billion
CAGR (%) 4.38%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Gabapentin Market

The Gabapentin Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of chronic pain and related conditions increasing the need for effective treatment options
    • Integration of gabapentin in multimodal pain management regimens promoting its adoption in clinical practice
    • Government initiatives and healthcare policies favoring the availability and affordability of essential medications
  • Market Restraints
    • Competition from alternative therapies and counterfeit and cheap-quality drugs
  • Market Opportunities
    • Growing need for gabapentin in veterinary medicine for pain management in pets and livestock
    • Emergence of gabapentin as a key drug in the treatment of fibromyalgia and related chronic pain syndromes
    • Development of gabapentin-based combination therapies for enhanced treatment efficacy in neurological disorders
  • Market Challenges
    • Increasing concerns over potential side effects and misuse

Porter's Five Forces: A Strategic Tool for Navigating the Gabapentin Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Gabapentin Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Gabapentin Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Gabapentin Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Gabapentin Market

A detailed market share analysis in the Gabapentin Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Gabapentin Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Gabapentin Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Gabapentin Market

A strategic analysis of the Gabapentin Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Gabapentin Market, highlighting leading vendors and their innovative profiles. These include AVEFLOR, a. s., BD Custom Manufacturing, Capital Resin Corporation, Chemplast Sanmar Limited, Con-Tech International., Custom Manufacturing Corporation, Custom Manufacturing Solutions, Dassault Systemes, Dassault Systemes S.E., East West Manufacturing, LLC, Evonik Industries AG, Formlabs Inc., Ganesh Group of Industries, Grand Prix International PLC, Hexagon AB, Monroe Engineering, LLC, Promega Corporation., Protocase Incorporated, RAS Polska Sp. z o.o., Sartorius AG, SHENZHEN WEIKE RAPID PROTOTYPING TECHNOLOGY CO. LTD, Siemens AG, Thomas Swan & Co. Ltd., and VWR International, LLC..

Market Segmentation & Coverage

This research report categorizes the Gabapentin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Capsule and Tablet.
  • Based on Route of Administration, market is studied across Oral and Parenteral.
  • Based on Medication, market is studied across Branded and Generic.
  • Based on Application, market is studied across Anxiety, Epilepsy, Neuropathic Pain, and Restless Legs Syndrome.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of chronic pain and related conditions increasing the need for effective treatment options
      • 5.1.1.2. Integration of gabapentin in multimodal pain management regimens promoting its adoption in clinical practice
      • 5.1.1.3. Government initiatives and healthcare policies favoring the availability and affordability of essential medications
    • 5.1.2. Restraints
      • 5.1.2.1. Competition from alternative therapies and counterfeit and cheap-quality drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing need for gabapentin in veterinary medicine for pain management in pets and livestock
      • 5.1.3.2. Emergence of gabapentin as a key drug in the treatment of fibromyalgia and related chronic pain syndromes
      • 5.1.3.3. Development of gabapentin-based combination therapies for enhanced treatment efficacy in neurological disorders
    • 5.1.4. Challenges
      • 5.1.4.1. Increasing concerns over potential side effects and misuse
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Formulation: High preference for capsules due to convenient and straightforward option
    • 5.2.2. Application : Widely utilized as an adjunct therapy for partial seizures to stabilize neuronal activity and reduce seizure frequency
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Gabapentin Market, by Product

  • 6.1. Introduction
  • 6.2. Capsule
  • 6.3. Tablet

7. Gabapentin Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parenteral

8. Gabapentin Market, by Medication

  • 8.1. Introduction
  • 8.2. Branded
  • 8.3. Generic

9. Gabapentin Market, by Application

  • 9.1. Introduction
  • 9.2. Anxiety
  • 9.3. Epilepsy
  • 9.4. Neuropathic Pain
  • 9.5. Restless Legs Syndrome

10. Gabapentin Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Americas Gabapentin Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Gabapentin Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Gabapentin Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Strides Pharma receives USFDA approval for neurology medication Gabapentin
    • 14.3.2. Lotus and Adalvo launch Gabapentin ER in South Korea
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AVEFLOR, a. s.
  • 2. BD Custom Manufacturing
  • 3. Capital Resin Corporation
  • 4. Chemplast Sanmar Limited
  • 5. Con-Tech International.
  • 6. Custom Manufacturing Corporation
  • 7. Custom Manufacturing Solutions
  • 8. Dassault Systemes
  • 9. Dassault Systemes S.E.
  • 10. East West Manufacturing, LLC
  • 11. Evonik Industries AG
  • 12. Formlabs Inc.
  • 13. Ganesh Group of Industries
  • 14. Grand Prix International PLC
  • 15. Hexagon AB
  • 16. Monroe Engineering, LLC
  • 17. Promega Corporation.
  • 18. Protocase Incorporated
  • 19. RAS Polska Sp. z o.o.
  • 20. Sartorius AG
  • 21. SHENZHEN WEIKE RAPID PROTOTYPING TECHNOLOGY CO. LTD
  • 22. Siemens AG
  • 23. Thomas Swan & Co. Ltd.
  • 24. VWR International, LLC.

LIST OF FIGURES

  • FIGURE 1. GABAPENTIN MARKET RESEARCH PROCESS
  • FIGURE 2. GABAPENTIN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GABAPENTIN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GABAPENTIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GABAPENTIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GABAPENTIN MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GABAPENTIN MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GABAPENTIN MARKET SIZE, BY MEDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GABAPENTIN MARKET SIZE, BY MEDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GABAPENTIN MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL GABAPENTIN MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS GABAPENTIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS GABAPENTIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES GABAPENTIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES GABAPENTIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. GABAPENTIN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. GABAPENTIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GABAPENTIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GABAPENTIN MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GABAPENTIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GABAPENTIN MARKET DYNAMICS
  • TABLE 7. GLOBAL GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GABAPENTIN MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GABAPENTIN MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GABAPENTIN MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GABAPENTIN MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GABAPENTIN MARKET SIZE, BY GENERIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GABAPENTIN MARKET SIZE, BY ANXIETY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GABAPENTIN MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GABAPENTIN MARKET SIZE, BY RESTLESS LEGS SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL GABAPENTIN MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL GABAPENTIN MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES GABAPENTIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 234. GABAPENTIN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 235. GABAPENTIN MARKET, FPNV POSITIONING MATRIX, 2023